The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects von Hurchla, M A, Garcia-Gomez, A, Hornick, M C, Ocio, E M, Li, A, Blanco, J F, Collins, L, Kirk, C J, Piwnica-Worms, D, Vij, R, Tomasson, M H, Pandiella, A, San Miguel, J F, Garayoa, M, Weilbaecher, K N

Volltext

The skinny on obesity and plasma cell myeloma: a review of the literature von Carson, K R, Bates, M L, Tomasson, M H

Volltext

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study von Uy, G L, Goyal, S D, Fisher, N M, Oza, A Y, Tomasson, M H, Stockerl-Goldstein, K, DiPersio, J F, Vij, R

Volltext

Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function von Uy, G.L., Peles, S., Fisher, N.M., Tomasson, M.H., DiPersio, J.F., Vij, R.

Volltext

High rates of reactivation of varicella zoster virus (VZV) associated with bortezomib (VELCADE) when given pre and post high dose chemotherapy (HDCT) von Peles, S., Uy, G.L., Fisher, N.M., Tomasson, M.H., DiPersio, J.F., Vij, R.

Volltext

Bortezomib does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation von Uy, G.L., Fisher, N.M., Devine, S.M., Adkins, D.R., Tomasson, M.H., Graubert, T.A., DiPersio, J.F., Vij, R.

Volltext